Recurrent platelet-derived growth factor receptor beta gene mutations in Kosaki overgrowth syndrome: a molecular and clinical overview.

OBJECTIVE Kosaki overgrowth syndrome (KOGS) is a rare genetic disorder linked to germline variants in the platelet-derived growth factor receptor beta gene (PDGFRB) that is characterized by postnatal overgrowth, hyperelastic skin, lipodystrophy, and craniofacial anomalies. This study aimed to summarize clinical and genetic data from reported KOGS cases and investigate the molecular consequences of two recurrent KOGS-associated PDGFRB variants. METHODS Clinical and genetic information from 17 previously published KOGS cases was reviewed. Molecular studies were performed using patient-derived fibroblasts and genetically modified cells transduced with the recurrent PDGFRB variants Trp566Arg and Pro584Arg. Downstream signaling and phosphorylation of PDGFRB tyrosine residues were assessed by immunoblotting and immunocytochemistry. RESULTS Both variants induced phosphorylation of specific PDGFRB tyrosine residues and activated downstream signaling pathways in the absence of ligand stimulation, which could contribute to the phenotypic overgrowth observed in KOGS. Immunocytochemistry revealed vesicle-like structures of phosphorylated PDGFRB (pY740), resembling wild-type cells stimulated with growth factor, thereby supporting the constitutive activation of PDGFRB in patient fibroblasts. Both variants showed sensitivity to the tyrosine kinase inhibitor imatinib. CONCLUSIONS Recurrent PDGFRB variants in KOGS cause ligand-independent activation of PDGFRB, contributing to the overgrowth phenotype. Imatinib may represent a potential targeted therapeutic option.

• Publication year

  2025

• Venue

  Clinical Dysmorphology

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MCD.0000000000000547PMID 41223009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corneal Vascularization Associated With a Novel PDGFRB Variant

  2023cited by this paper
• Activated EGFR and PDGFR internalize in separate vesicles and downstream AKT and ERK1/2 signaling are differentially impacted by cholesterol depletion.

  2023cited by this paper
• Kosaki overgrowth syndrome due to a novel de novo PDGFRB variant

  2021cited by this paper
• Positive response to imatinib in PDGFRB‐related Kosaki overgrowth syndrome

  2021cited by this paper
• Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions

  2021cited by this paper
• Kosaki Overgrowth Syndrome: Report of a Family with a Novel PDGFRB Variant

  2021cited by this paper
• PDGF receptor mutations in human diseases

  2021cited by this paper
• Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy

  2020cited by this paper
• Carpal tunnel syndrome in paediatric patients: A novel association with Kosaki overgrowth syndrome

  2020cited by this paper
• Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications

  2020cited by this paper
• Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet‐derived growth factor receptor‐beta

  2019cited by this paper
• Constitutive activation of the PI3K‐AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome

  2019cited by this paper
• A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome

  2018cited by this paper
• Phenotype expansion and development in Kosaki overgrowth syndrome

  2018cited by this paper
• Expansion of the phenotype of Kosaki overgrowth syndrome

  2017cited by this paper
• Multiple routes of endocytic internalization of PDGFRβ contribute to PDGF-induced STAT3 signaling

  2017cited by this paper
• PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib

  2016cited by this paper
• Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies

  2016cited by this paper
• The Ubiquitin Ligases c-Cbl and Cbl-b Negatively Regulate Platelet-derived Growth Factor (PDGF) BB-induced Chemotaxis by Affecting PDGF Receptor β (PDGFRβ) Internalization and Signaling*

  2016cited by this paper
• Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation.

  2015cited by this paper
• Endocytosis of receptor tyrosine kinases.

  2013cited by this paper
• Monitoring imatinib plasma concentrations in chronic myeloid leukemia

  2011cited by this paper
• Activation of protein kinase C alpha is necessary for sorting the PDGF beta-receptor to Rab4a-dependent recycling.

  2009cited by this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cited by this paper
• Loss of T-cell protein tyrosine phosphatase induces recycling of the platelet-derived growth factor (PDGF) beta-receptor but not the PDGF alpha-receptor.

  2006cited by this paper
• Platelet-derived Growth Factor Receptor-mediated Signal Transduction from Endosomes*

  2004cited by this paper
• Switching on kinases: oncogenic activation of BRAF and the PDGFR family

  2004cited by this paper
• Juxtamembrane autoinhibition in receptor tyrosine kinases

  2004cited by this paper
• Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β Receptor*

  2002cited by this paper
• Full Activation of the Platelet-derived Growth Factor β-Receptor Kinase Involves Multiple Events*

  1998cited by this paper

• No citing papers are available for this paper.